Today is shaping up negative for AbCellera Biologics Inc. (NASDAQ:ABCL) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Revenue estimates were cut sharply as the analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well. Surprisingly the share price has been buoyant, rising 19% to US$6.93 in the past 7 days. It will be interesting to see if the downgrade has an impact on buying demand for the company's shares.

After the downgrade, the consensus from AbCellera Biologics' seven analysts is for revenues of US$25m in 2026, which would reflect a concerning 62% decline in sales compared to the last year of performance. Prior to the latest estimates, the analysts were forecasting revenues of US$32m in 2026. It looks like forecasts have become a fair bit less optimistic on AbCellera Biologics, given the sizeable cut to revenue estimates.

There was no particular change to the consensus price target of US$10.75, with AbCellera Biologics' latest outlook seemingly not enough to result in a change of valuation.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. One more thing stood out to us about these estimates, and it's the idea that AbCellera Biologics' decline is expected to accelerate, with revenues forecast to fall at an annualised rate of 86% to the end of 2026. This tops off a historical decline of 54% a year over the past five years. Compare this against analyst estimates for companies in the broader industry, which suggest that revenues (in aggregate) are expected to grow 6.9% annually. So it's pretty clear that, while it does have declining revenues, the analysts also expect AbCellera Biologics to suffer worse than the wider industry.

The Bottom Line

The clear low-light was that analysts slashing their revenue forecasts for AbCellera Biologics this year. They also expect company revenue to perform worse than the wider market. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on AbCellera Biologics after today.

Of course, there's always more to the story. At least one of AbCellera Biologics' seven analysts has provided estimates out to 2028, which can be seen for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.